Leukemia research reports · 2026
Gemcitabine, dexamethasone and cisplatin with or without rituximab is highly effective as a mobilization regimen in relapsed or refractory lymphoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Taillefer Vincent T, Emond Marianne, Leblanc Marie-Hélène, Doucet Stephane, Adam Jean-Philippe
Аннотация
INTRODUCTION: A combination of Gemcitabine, Dexamethasone and Cisplatin (GDP) with or without rituximab (±R) is an outpatient treatment widely used for relapsed or refractory (R/R) lymphoma. Limited data are available on stem cell mobilization following GDP treatment.
METHOD: A retrospective multicenter study was conducted from January 1st, 2014, to December 31st, 2020. Patients received GDP±R before autologous stem cell transplantation (ASCT) and were mobilized with either GDP±R or intermediate-dose cyclophosphamide (ID-CY). The primary objective was to determine the percentage of patients achieving ≥2 × 106 CD34+/kg, median CD34+ yield, and number of apheresis days. The secondary objective compared these results with ID-CY.
RESULTS: Ninety-two patients (median age 54) were treated for diffuse large B-cell (40%), Hodgkin (36%), or follicular lymphoma (16%). Of these, 83 were mobilized with GDP±R and 9 with ID-CY. G-CSF was administered at 5 mcg/kg (61%) or 10 mcg/kg (37%) daily, typically starting on day 9, after two GDP cycles. A successful stem cell collection at the first attempt occurred in 96% of GDP±R patients, and 94% of patients proceeded to ASCT. No significant difference was found between GDP±R and ID-CY in terms of successful collection (96% vs. 100%, p=NS), but fewer hospitalizations occurred within 21 days of mobilization (1% vs. 22%, p = 0.02).
CONCLUSION: This study demonstrated the feasibility of performing a peripheral blood stem cell mobilization at day 15 following GDP±R. It is highly effective and represents a better option due to its simplicity of administration, low rate of hospitalization and low cost.
METHOD: A retrospective multicenter study was conducted from January 1st, 2014, to December 31st, 2020. Patients received GDP±R before autologous stem cell transplantation (ASCT) and were mobilized with either GDP±R or intermediate-dose cyclophosphamide (ID-CY). The primary objective was to determine the percentage of patients achieving ≥2 × 106 CD34+/kg, median CD34+ yield, and number of apheresis days. The secondary objective compared these results with ID-CY.
RESULTS: Ninety-two patients (median age 54) were treated for diffuse large B-cell (40%), Hodgkin (36%), or follicular lymphoma (16%). Of these, 83 were mobilized with GDP±R and 9 with ID-CY. G-CSF was administered at 5 mcg/kg (61%) or 10 mcg/kg (37%) daily, typically starting on day 9, after two GDP cycles. A successful stem cell collection at the first attempt occurred in 96% of GDP±R patients, and 94% of patients proceeded to ASCT. No significant difference was found between GDP±R and ID-CY in terms of successful collection (96% vs. 100%, p=NS), but fewer hospitalizations occurred within 21 days of mobilization (1% vs. 22%, p = 0.02).
CONCLUSION: This study demonstrated the feasibility of performing a peripheral blood stem cell mobilization at day 15 following GDP±R. It is highly effective and represents a better option due to its simplicity of administration, low rate of hospitalization and low cost.